Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells

Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to evolve, with the development of genome analysis technology and the advent of molecular targeted drugs including tyrosine kinase inhibitors. Nevertheless, acquired drug resistance to molecular targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshioka, Takahiro, Shien, Kazuhiko, Takeda, Tatsuaki, Takahashi, Yuta, Kurihara, Eisuke, Ogoshi, Yusuke, Namba, Kei, Torigoe, Hidejiro, Sato, Hiroki, Tomida, Shuta, Yamamoto, Hiromasa, Soh, Junichi, Fujiwara, Toshiyoshi, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676122/
https://www.ncbi.nlm.nih.gov/pubmed/31162771
http://dx.doi.org/10.1111/cas.14089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676122/
https://www.ncbi.nlm.nih.gov/pubmed/31162771
http://dx.doi.org/10.1111/cas.14089

Ejemplares similares